PODD · Healthcare

INSULET CORP

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-08

• Guidance and OutlookImportance 83 · Surprise 92
  Insulet lowered its fiscal 2026 GAAP revenue growth guidance to 21%–23% because of a softer second half, particularly for U.S. Omnipod sales. The company reduced its full-year U.S. revenue-growth outlook to 17%–19%…
• Revenue Performance and MixImportance 47 · Surprise 48
  Insulet reported second-quarter 2026 revenue of $801.7 million for the three months ended June 30, 2026, up 23.5% year over year and 22.7% in constant currency. Revenue exceeded the high end of the company’s 20%–22%…

News · 2026-08-06

• Guidance and OutlookImportance 83 · Surprise 92
  Insulet lowered its fiscal 2026 GAAP revenue growth guidance to 21%–23% because of a softer second half, particularly for U.S. Omnipod sales. The company reduced its full-year U.S. revenue-growth outlook to 17%–19%…
• Omnipod Quality CorrectionsImportance 59 · Surprise 60
  Insulet’s Omnipod platform was affected by two voluntary medical-device corrections tied to manufacturing and quality-control issues. Third-party reports said approximately 7 million Pods were subject to corrections,…
• Revenue Performance and MixImportance 47 · Surprise 48
  Insulet reported second-quarter 2026 revenue of $801.7 million for the three months ended June 30, 2026, up 23.5% year over year and 22.7% in constant currency. Revenue exceeded the high end of the company’s 20%–22%…
• Type 2 Retention ChallengesImportance 40 · Surprise 42
  Insulet attributed the U.S. outlook reduction to weaker-than-anticipated retention and utilization among Type 2 diabetes patients. Management identified execution challenges during the initial 90-day onboarding period…
• Net Income and EPS PerformanceImportance 9 · Surprise 6
  Insulet reported second-quarter adjusted EPS of $1.66, exceeding the FactSet estimate of $1.45 and the Zacks consensus estimate of $1.44. Statutory EPS was reported at $1.37 per share. Net income was $95.0 million for…

10-Q · 2026-08-05

• Share Repurchase ProgramImportance 77 · Surprise 82
  Insulet repurchased $300.0 million of common stock during the first six months of 2026, compared with $30.1 million in the prior-year period. The company repurchased 1.251 million shares during the six months ended…
• Liquidity and Debt PositionImportance 71 · Surprise 48
  Cash and cash equivalents declined $181.2 million to $534.9 million at June 30, 2026 from $716.1 million at December 31, 2025. Net cash provided by operating activities was $202.2 million for the first six months,…
• Capital Expenditures ProgramImportance 71 · Surprise 82
  Capital expenditures increased 83.8% to $56.8 million for the first six months of 2026 from $30.9 million in the prior-year period. Insulet invested an additional $8.3 million in developed software during the period,…
• FX / Currency ImpactImportance 70 · Surprise 56
  International Omnipod revenue increased $156.5 million, or 46.3%, to $494.6 million for the six months ended June 30, 2026. Currency exchange contributed a favorable 7.9% impact, while underlying growth was 38.4%.…
• International Omnipod Revenue GrowthImportance 69 · Surprise 56
  U.S. Omnipod revenue increased 20.1% to $544.1 million in the second quarter of 2026 and 24.0% to $1.060 billion for the first six months. International Omnipod revenue grew 35.5% to $251.8 million in the quarter and…
• International Market ExpansionImportance 66 · Surprise 74
  Insulet launched Omnipod 5 and Omnipod Discover in five Middle Eastern countries in February 2026 and launched the products in Spain in July 2026. The company is building international teams and advancing regulatory,…
• Trade Secret LitigationImportance 65 · Surprise 60
  Insulet obtained a $59.4 million damages award and worldwide permanent injunction against EOFlow defendants over misappropriation of four Omnipod-related trade secrets. On May 28, 2026, the Federal Circuit reversed the…
• Research and Development ExpenseImportance 64 · Surprise 56
  Research and development expense increased 20.0% to $88.1 million in the second quarter of 2026 and 33.7% to $177.8 million for the first six months. Selling, general and administrative expense increased 33.8% to…
• End-Market Demand TrendsImportance 64 · Surprise 56
  Omnipod product revenue increased 24.6% in the second quarter and 30.3% in the first six months of 2026, driven primarily by higher sales volume and a growing customer base. U.S. Omnipod revenue grew 20.1% in the…
• Free Cash FlowImportance 64 · Surprise 56
  Free cash flow decreased $83.9 million, or 36.6%, to $145.4 million for the six months ended June 30, 2026 from $229.4 million. The decline resulted primarily from higher working-capital outflows and capital…
• Semiconductor Purchase CommitmentImportance 60 · Surprise 48
  Insulet entered into a 2026 purchase agreement with NXP USA for semiconductor chips used in its products. The commitment totaled approximately $77.4 million as of June 30, 2026, exceeding the materiality threshold for…
• Revenue Performance and MixImportance 59 · Surprise 48
  Total revenue increased 23.5% year over year to $801.7 million in the second quarter of 2026 from $649.1 million, and increased 28.4% to $1.563 billion for the six months ended June 30, 2026. Omnipod product revenue…
• Gross Margin DriversImportance 59 · Surprise 48
  Three-month cost of revenue increased $42.3 million, or 21.5%, to $239.1 million, while gross margin expanded 50 basis points to 70.2% from 69.7%. The quarterly margin improvement was primarily driven by manufacturing…
• Product Safety CorrectionsImportance 59 · Surprise 60
  During the six months ended June 30, 2026, Insulet issued two voluntary medical device corrections, in March and May, for separate manufacturing issues that could cause a tear in the cannula of certain Omnipod…
• Operating Cash Flow TrendsImportance 59 · Surprise 48
  Operating cash flow was $202.2 million for the six months ended June 30, 2026, down from $260.3 million in the prior-year period. A $94.5 million working-capital outflow included a $76.9 million increase in accounts…
• Inventory Build and Manufacturing ExpansionImportance 57 · Surprise 50
  Insulet increased inventories by $34.9 million during the first six months of 2026 as part of a planned build to satisfy growing demand. Capital expenditures increased to $56.8 million, primarily for machinery,…
• Interest Rate OutlookImportance 57 · Surprise 64
  Interest expense was $28.2 million for the six months ended June 30, 2026, with higher expense from the 6.5% senior unsecured notes issued in March 2025 and interest-rate swaps renewed at higher rates in April 2025.…
• Income Tax Rate ChangesImportance 51 · Surprise 64
  The effective tax rate was 19.7% for the first six months of 2026, down from 24.3% in the prior-year period. Income tax expense increased to $45.6 million from $18.6 million because pretax income increased to $231.7…
• Drug Delivery Revenue DeclineImportance 51 · Surprise 64
  Drug Delivery revenue consists substantially of pod sales to Amgen for the Neulasta Onpro kit, which helps reduce infection risk after intensive chemotherapy. Revenue declined to $9.1 million for the first six months…
• Securities Fraud InvestigationImportance 44 · Surprise 60
  On July 2, 2026, a putative securities class action was filed in the U.S. District Court for the District of Massachusetts against Insulet and certain current and former executives and directors. The complaint alleges…
• Manufacturing CapacityImportance 37 · Surprise 42
  Insulet is strengthening global manufacturing capabilities to support continued Omnipod growth. The company is investing in a new manufacturing plant in Costa Rica, with construction financed through a build-to-suit…
• Trade Policy and TariffsImportance 37 · Surprise 42
  Insulet does not expect tariffs to have a significant impact on gross margin in 2026. However, management states that eliminating the current exemption for certain medical devices would materially affect future-year…
• U.S. Tax Law ChangesImportance 37 · Surprise 42
  The United States enacted the One Big Beautiful Bill Act during 2025, extending certain Tax Cuts and Jobs Act provisions and changing international tax rules through 2027. Insulet’s 2026 effective tax rate is affected…
• Products and TechnologyImportance 31 · Surprise 42
  Omnipod 5 is Insulet’s current-generation tubeless automated insulin delivery system, integrating with Dexcom G6 and G7 continuous glucose monitors and Abbott’s FreeStyle Libre 2 Plus sensor in various markets. In June…
• Omnipod Product DevelopmentImportance 31 · Surprise 42
  Insulet increased research and development investment to support its Omnipod platform and pipeline products. Development priorities include Omnipod 6, described as the next-generation automated insulin delivery system,…
• Pod Configuration TransitionImportance 31 · Surprise 42
  Insulet is transitioning to new Pod configurations, which increased its inventory excess and obsolescence reserve during the first six months of 2026. The transition also contributed to lower gross margin in that…
• Pillar Two Global Minimum TaxImportance 17 · Surprise 24
  The OECD and participating countries continue implementing a 15% global minimum corporate tax under Pillar Two. The Netherlands and United Kingdom enacted legislation implementing aspects of Pillar Two during 2025,…
• Distribution ChannelsImportance 16 · Surprise 6
  Insulet sells its U.S. products through the pharmacy channel, which improves access and affordability by avoiding an upfront investment. The company is also increasing awareness through direct-to-consumer advertising…

8-K · 2026-08-05

• Guidance and OutlookImportance 80 · Surprise 68
  Insulet maintained full-year 2026 total revenue growth guidance of 20% to 22% in constant currency, compared with prior guidance of 21% to 23%. Full-year Total Omnipod constant-currency growth guidance was reduced to…
• Guidance / OutlookImportance 80 · Surprise 68
  Insulet projects 2026 total revenue growth of 20%–22% in constant currency, reduced from prior guidance of 21%–23%. Updated full-year guidance includes U.S. Omnipod growth of 17%–19%, international Omnipod growth of…
• Net Income and ProfitabilityImportance 77 · Surprise 82
  Second-quarter net income increased to $95.0 million from $22.5 million, and diluted EPS rose to $1.37 from $0.32. The prior-year quarter included an $84.4 million loss on extinguishment of debt related to…
• Gross Margin DriversImportance 73 · Surprise 66
  GAAP gross profit increased to $562.6 million from $452.2 million, while GAAP gross margin was 70.2% of revenue. Estimated warranty and related costs associated with voluntary medical device corrections reduced…
• Operating Expense TrendsImportance 70 · Surprise 56
  Second-quarter research and development expense increased 20.0% to $88.1 million from $73.4 million, reflecting continued investment in Omnipod products and technology. Selling, general and administrative expense…
• Geographic Market CommentaryImportance 64 · Surprise 56
  International Omnipod revenue grew 35.5% year over year to $251.8 million in the second quarter, or 32.9% in constant currency. U.S. Omnipod revenue increased 20.1% to $544.1 million. Spain became the 26th country…
• Free Cash Flow and CapexImportance 58 · Surprise 56
  Insulet generated $145.4 million of free cash flow during the first six months of 2026, down from $229.4 million in the prior-year period. Net cash provided by operating activities declined to $202.2 million from…
• Operating Income and MarginsImportance 57 · Surprise 50
  Second-quarter GAAP operating income increased to $129.7 million from $121.1 million, but GAAP operating margin declined 250 basis points to 16.2% of revenue. The margin comparison included $25.0 million of voluntary…
• Regulatory Approval MilestonesImportance 53 · Surprise 60
  Insulet recorded estimated warranty costs associated with voluntary medical device corrections issued in March and May 2026. The corrections generated $21.9 million of gross-profit costs and $25.0 million of adjusted…
• Revenue Performance and MixImportance 52 · Surprise 30
  Second-quarter 2026 revenue was $801.7 million, up 23.5% year over year and 22.7% in constant currency. Total Omnipod revenue increased 24.6% to $795.9 million, comprising 99% of total revenue, while Drug Delivery…
• Liquidity and Debt PositionImportance 52 · Surprise 30
  Cash and cash equivalents were $534.9 million at June 30, 2026, down from $716.1 million at December 31, 2025. Total debt was approximately $948.4 million, consisting of $18.9 million of current debt and $929.5 million…
• Market Demand TrendsImportance 52 · Surprise 48
  Second-quarter total revenue increased 23.5% year over year to $801.7 million, exceeding the company’s 20%-22% constant-currency guidance range. Total Omnipod revenue rose 24.6% to $795.9 million, led by U.S. Omnipod…
• Product Launch and TransitionImportance 31 · Surprise 42
  Insulet launched Omnipod 5 and Omnipod Discover in Spain, bringing Omnipod sales to 26 countries and Omnipod 5 availability to 20 countries. The company expanded the Omnipod 5 ecosystem with a next-generation algorithm…
• Distribution Channels and PartnershipsImportance 31 · Surprise 42
  Insulet expanded access to its tubeless diabetes technology in Spain through the launch of Omnipod 5 and Omnipod Discover. The Omnipod 5 ecosystem also expanded through compatibility with Abbott’s FreeStyle Libre 3…
• Manufacturing capacity expansionImportance 31 · Surprise 42
  Insulet launched Omnipod 5 and Omnipod Discover in Spain in the second quarter of 2026. Spain became the 26th country where Insulet sells Omnipod and the 20th country where Omnipod 5 is available. The launch expands…

News · 2026-08-05

• Guidance and OutlookImportance 83 · Surprise 92
  Insulet lowered its fiscal 2026 GAAP revenue growth guidance to 21%–23% because of a softer second half, particularly for U.S. Omnipod sales. The company reduced its full-year U.S. revenue-growth outlook to 17%–19%…
• Omnipod Quality CorrectionsImportance 59 · Surprise 60
  Insulet’s Omnipod platform was affected by two voluntary medical-device corrections tied to manufacturing and quality-control issues. Third-party reports said approximately 7 million Pods were subject to corrections,…
• Revenue Performance and MixImportance 47 · Surprise 48
  Insulet reported second-quarter 2026 revenue of $801.7 million for the three months ended June 30, 2026, up 23.5% year over year and 22.7% in constant currency. Revenue exceeded the high end of the company’s 20%–22%…
• Insulin Pump CompetitionImportance 46 · Surprise 42
  Insulet is preparing for heightened competition in the insulin-pump market anticipated in 2027. The company has benefited from limited direct competition in tubeless insulin pumps for roughly two decades, supporting…
• Type 2 Retention ChallengesImportance 40 · Surprise 42
  Insulet attributed the U.S. outlook reduction to weaker-than-anticipated retention and utilization among Type 2 diabetes patients. Management identified execution challenges during the initial 90-day onboarding period…
• Type 2 Diabetes RetentionImportance 40 · Surprise 42
  Insulet reported weaker-than-expected retention and utilization among U.S. Type 2 diabetes patients using Omnipod. The company attributed the issue to execution challenges during the initial 90-day onboarding period,…
• International Omnipod DemandImportance 26 · Surprise 24
  Omnipod demand remained strong across U.S. and international markets, with global active customers surpassing 600,000. Omnipod 5 was described as leading the market, supporting continued adoption of Insulet’s tubeless…
• Net Income and EPS PerformanceImportance 9 · Surprise 6
  Insulet reported second-quarter adjusted EPS of $1.66, exceeding the FactSet estimate of $1.45 and the Zacks consensus estimate of $1.44. Statutory EPS was reported at $1.37 per share. Net income was $95.0 million for…

News · 2026-08-04

• International Omnipod DemandImportance 26 · Surprise 24
  Omnipod demand remained strong across U.S. and international markets, with global active customers surpassing 600,000. Omnipod 5 was described as leading the market, supporting continued adoption of Insulet’s tubeless…
• Net Income and EPS PerformanceImportance 9 · Surprise 6
  Insulet reported second-quarter adjusted EPS of $1.66, exceeding the FactSet estimate of $1.45 and the Zacks consensus estimate of $1.44. Statutory EPS was reported at $1.37 per share. Net income was $95.0 million for…